Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART) : a multicentre, prospective, randomised, open-label, blinded-endpoint trial
Citation
Mackenzie , I S , Hawkey , C J , Ford , I , Greenlaw , N , Pigazzani , F , Rogers , A , Struthers , A D , Begg , A G , Wei , L , Avery , A J , Taggar , J S , Walker , A , Duce , S L , Barr , R J , Dumbleton , J S , Rooke , E D , Townend , J N , Ritchie , L D , MacDonald , T M , Ahmed , H , Arthur , P , Aziz , J , Barnes , L , Boyle , S , Brighton , T , Brown , M , Caulfield , M , Dawson , J , Denvir , M , Doney , A SF , Doshi , S , Dryburgh , M , Eddleston , M , Finlayson , J , Fuat , A , Furnace , J , Grieve , JW K , Guthrie , G , Ham , S , Isaard , E , Jennings , C , Johnson , R , Kerr , C , Khan , S , Krishnan , K , Long , S , Mackintosh , A , Macleod , M J , McCormack , T , Weir , C & ALL-HEART Study Group 2022 , ' Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART) : a multicentre, prospective, randomised, open-label, blinded-endpoint trial ' , The Lancet , vol. 400 , no. 10359 , pp. 1195-1205 . https://doi.org/10.1016/S0140-6736(22)01657-9
Rights
https://creativecommons.org/licenses/by/4.0/